Shanghai Shyndec Pharmaceutical (600420.SH): Guoyao Rongsheng Vitamin B6 Injection increases specification and passes consistency evaluation.
State-owned China National Pharmaceutical Group Corporation (Sinopharm) (stock code: 600420.SH) issued an announcement recently that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd...
Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, Guoyao Group Rongsheng Pharmaceutical Co., Ltd. (referred to as Guoyao Rongsheng), recently received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration. The notice approved the increase in specifications for vitamin B6 injection and passed the generic drug quality and efficacy consistency evaluation, and issued a drug approval number.
The increase in specifications for Guoyao Rongsheng vitamin B6 injection and passing the consistency evaluation will be beneficial for the future market expansion and sales of the product. The above-mentioned matters will not have a significant impact on the company's current operating performance.
Related Articles

US Stock Market Move | ACCL.US, a company controlled by Zhuo Yuan, has landed on the US stock market with a 1.75% increase in trading at the opening.

US Stock Market Move | NVIDIA Corporation holds Concept Stock Coreweave (CRWV.US), which fell more than 7%.

US Stock Market Move | Reach a $1.085 billion cooperation agreement with domestic and foreign pharmaceutical companies, Rani Therapeutics (RANI.US) soars over 265%.
US Stock Market Move | ACCL.US, a company controlled by Zhuo Yuan, has landed on the US stock market with a 1.75% increase in trading at the opening.

US Stock Market Move | NVIDIA Corporation holds Concept Stock Coreweave (CRWV.US), which fell more than 7%.

US Stock Market Move | Reach a $1.085 billion cooperation agreement with domestic and foreign pharmaceutical companies, Rani Therapeutics (RANI.US) soars over 265%.

RECOMMEND